An updated review of acitretin – a systemic retinoid for the treatment of psoriasis

Bibliography

• Available from: http://www.psoriasis.org/about/stats
   Google Scholar
• Lebwohl M, Menter A, Koo J, Feldman SR. Case studies in severe psoriasis: a clinical strategy. J Dermatol Treat 2003;14(Suppl 2):26-46
   PubMedGoogle Scholar
• Rapp S, Feldman S, Lyn Exum J, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41(3):401-7
   PubMed Web of Science ®Google Scholar
• Finlay A, Khan G, Luscombe D, Salek M. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol 1990;123:751-6
   PubMed Web of Science ®Google Scholar
• Sander HM, Morris LF, Phillips CM, et al. The annual cost of psoriasis. J Am Acad Dermatol 1993;28:422-9
   PubMed Web of Science ®Google Scholar
• Koo J. Sequential therapy of psoriasis. Introducing a new therapeutic paradigm for better clinical results. J Am Acad Dermatol 1999;41:S25-8
   PubMed Web of Science ®Google Scholar
• Parrish JA, Jaenicke J. Action spectrum for phototherapy of psoriasis. J Invest Dermatol 1981;76(5):359-62
   PubMed Web of Science ®Google Scholar
• Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband UVB phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004;151:283-97
   PubMed Web of Science ®Google Scholar
• Honigsmann H. Phototherapy for psoriasis. Clin Dermatol 2001;26:343-50
   Web of Science ®Google Scholar
• Feldman SR, Koo JYM, Lebwohl MG, et al. The psoriasis and psoriatic arthritis pocket guide. Treatment algorithms and management options. Natl Psoriasis Found 2005
   Google Scholar
• Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 1994;73(11):2759-64
   PubMed Web of Science ®Google Scholar
• Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-up Study. N Engl J Med 1997;336(15):1041-5
   PubMed Web of Science ®Google Scholar
• Stern RS, Liebman EJ, Väkevä L. PUVA follow-up study: oral psoralen and ultraviolet light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998;90(17):1278-84
   PubMed Web of Science ®Google Scholar
• Murase JE, Lee EE, Koo J. Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy. Int J Dermatol 2005;44(12):1016-21
   PubMed Web of Science ®Google Scholar
• Mylan Pharmaceuticals, Inc. Methotrexate prescribing information. Mylan Pharmaceuticals, Inc., Morgantown (WV), USA; 2004
   Google Scholar
• Novartis Pharmaceutical, Corp. Neoral® (cyclosporine) prescribing information. Novartis Pharmaceutical Corp., East Hanover, NJ: USA; 2005
   Google Scholar
• Immunex Corp. Enbrel® (etanercept) prescribing information. Immunex Corp., Thousand Oaks, CA: USA; 2005
   Google Scholar
• Genentech, Inc. Raptiva® (efalizumab) prescribing information. Genentech, Inc., San Francisco, CA: USA; 2005
   Google Scholar
• Astellas, Corp. Amevive® (alefacept) prescribing information. Astellas Corp., Cambridge, MA: USA; 2005
   Google Scholar
• Centocor, Inc. Remicade® (infliximab) prescribing information. Centocor, Inc., Malvern, PA: USA; 2004
   Google Scholar
• Abbott, Inc. Humira (adalimumab) prescribing information. Abbott, Inc., North Chicago, IL: USA; 2008
   Google Scholar
• Khera P, Koo JYM. A review of the chemopreventative and chemotherapeutic effects of topical and oral retinoids for both curaneous and internal neoplasms. J Drugs Dermatol 2005;4(4):432-47
   PubMedGoogle Scholar
• Yamauchi PS, Rizk D, Kormeili T, et al. Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol 2003;49(2 Suppl):S66-77
   Google Scholar
• Chandraratna RA. Rational design of receptor-selective retinoids. J Am Acad Dermatol 1998;39:S124-8
   PubMed Web of Science ®Google Scholar
• Kang S, Li SY, Voorhees JJ. Pharmacology and molecular action of retinoids and vitamin D in skin. J Invest Dermatol Symposium Proc 1996;1:15-21
   PubMedGoogle Scholar
• Rowe A. Retinoids X receptors. Int J Biochem Cell Biol 1997;29:276-8
   Google Scholar
• Stiefel Laboratories. Soriatane (acitretin) prescribing information. Stiefel Laboratories, Inc., Coral Gables, FL: USA; 2007
   Google Scholar
• Larsen FG, Jakobsen P, Knudsen J, et al. Conversion of acitretin to etritinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1998;100:623-7
   Google Scholar
• McNamara PJ, Jewell RC, Jensen BK, Brindley CJ. Food increases the bioavailability of acitretin. J Clin Pharmacol 1988;28:1051-5
   PubMed Web of Science ®Google Scholar
• Leon A, Nguyen A, Letsinger J, Koo J. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. Exp Opin Pharmacother 2007;8(5):617-32
   PubMed Web of Science ®Google Scholar
• Kragballe K, Jansen CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Acta Derm Venereol 1989;69:35-40
   PubMed Web of Science ®Google Scholar
• Murray HE, Anhalt AW, Lessard R, et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter trial. J Am Acad Dermatol 1991;24:598-602
   PubMed Web of Science ®Google Scholar
• Ling MR. Acitretin: optimal dosing strategies. J Am Acad Dermatol 1999;41(3):S2-6
   Google Scholar
• Ozawa A, Ohkido M, Haruki Y, et al. Treatment of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol 1999;26:141-9
   PubMedGoogle Scholar
• Kim HS, Kim GM, Kim SY. Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy. Pediatr Dermatol 2006;23(3):306-8
   PubMed Web of Science ®Google Scholar
• Available from: https://www.ipledgeprogram.com
   Google Scholar
• Van De Kerkhof PC, Cambazard F, Hutchinson PE, et al. The effect of addition of calcipotriol ointment to acitretin therapy in psoriasis. Br J Dermatol 1998;138:84-9
   PubMed Web of Science ®Google Scholar
• Giannetti A, Coppini M, Bertazonni MG, et al. Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate-severe psoriasis. J Eur Acad Dermatol Venereol 1999;13:91-5
   PubMed Web of Science ®Google Scholar
• Rim JH, PAark JY, Choe YB, Youn JI. The efficacy of calcipotriol + acitretin combination therapy for psoriasis. Am J Clin Dermatol 2003;4(7):507-10
   PubMed Web of Science ®Google Scholar
• Lauharanta J, Geiger JM. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol 1989;121:107-12
   PubMed Web of Science ®Google Scholar
• Tanew A, Guggenbichler A, Honigsmann H, et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991;26:682-4
   Google Scholar
• Saurat JH, Geiger JM, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA, and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988;177:218-24
   PubMedGoogle Scholar
• Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiologic study. Lancet 1991;338:91-3
   PubMed Web of Science ®Google Scholar
• Van De Kerkhof PC, De Rooij MJ. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporine treatment: response to longterm acitretin maintenance. Br J Dermatol 1997;136:275-8
   PubMed Web of Science ®Google Scholar
• Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003;49(4):644-50
   PubMed Web of Science ®Google Scholar
• Muchenberger S, Schof E, Simon JC. The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis. Br J Dermatol 1997;137:587-9
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Rizk D, Kormili T, et al. Systemic retinoids. In: Weinstein GD, Gottlieb AB, editors, therapy of moderate-to-severe psoriasis. Marcel Dekker, Inc.: New York, NY, USA; 2003. p. 137-50
   Google Scholar
• Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989;120:665-70
   PubMed Web of Science ®Google Scholar
• Lowe N, Prystowsky JH, Bourget T, et al. Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24:591-4
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Sommerburg C, Braun-Falco O, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 1990;126:482-6
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999;41(3 Pt 2):S22-4
   PubMed Web of Science ®Google Scholar
• Spuls PI, Rozenbilt, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. J Dermatol Treat 2003;14(Suppl 2):17-20
   PubMedGoogle Scholar
• Lowenthal KE, Horn PJ, Kalb RE. Concurrent use of methotrexate and acitretin revisited. J Dermatol Treat 2008;19:22-6
   PubMed Web of Science ®Google Scholar
• Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002;146:118-21
   PubMed Web of Science ®Google Scholar
• Conley J, Nanton J, Dhawan S, et al. Novel combination regimens: biologics and acitretin for the treatment of psoriasis – a case series. J Dermatol Treat 2006;17:86-9
   PubMed Web of Science ®Google Scholar
• Otley CC, Stasko T, Tope WD, et al. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006;32:562-8
   PubMed Web of Science ®Google Scholar
• Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995;13(8):1933-8
   PubMed Web of Science ®Google Scholar
• McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999;140(4):656-60
   PubMed Web of Science ®Google Scholar
• Euvrard S, Kanitakis J, Thivolet J, Claudy A. Retinoids for the management of dermatological complications of organ transplantation. BioDrugs 1997;8(3):176-84
   PubMed Web of Science ®Google Scholar
• Euvard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91
   PubMed Web of Science ®Google Scholar
• Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40:177-86
   PubMed Web of Science ®Google Scholar
• Hartevelt MM, Bavinck JN, Kootte AMM, et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990;49:506-9
   PubMed Web of Science ®Google Scholar
• Lindelöf B, Sigurgeirsson B, Gäbel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000;143:513-9
   PubMed Web of Science ®Google Scholar
• Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997;133(6):711-5
   PubMed Web of Science ®Google Scholar
• Erkek E, Karaduman A, Akcan Y, et al. Psoriasis associated with HCV and Exacerbated by interferon alpha: Complete clearance with acitretin during interferon alpha treatment for chronic active hepatitis. Dermatology 2000;201:179-80
   PubMed Web of Science ®Google Scholar
• Stiefel Research Institute. Data on file
   Google Scholar
• Stuart BH, Litt IF. Tetracycline-associated intracranial hypertension in an adolescent: a complication of systemic acne therapy. J Pediatr 1978;92:679-80
   PubMed Web of Science ®Google Scholar
• Wolverton SE. Retinoids. In: Wolverton SE, Wilkins JK, Saunders WB, editors, Systemic drugs for skin diseases. Philadelphia, PA: USA; 1991;187-218
   Google Scholar
• Starling J, Koo J. Evidence based or theoretical concern? Pseudotumor cerebri and depression as acitretin side effects. J Drugs Dermatol 2005;4:690-6
   PubMedGoogle Scholar
• Walters BN, Gubbay SS. Tetracycline and benign intracranial hypertension: report of 5 cases. Br Med J (Clin Res Ed) 1981;282:19-20
   PubMed Web of Science ®Google Scholar
• Bigby M, Stern RS. Adverse reactions to isotretinoin. A report from the Adverse Drug Reaction Reporting System. J Am Acad Dermatol 1988;18(3):543-52
   PubMed Web of Science ®Google Scholar
• Lee AG. Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis 1995;55(3):165-8
   PubMed Web of Science ®Google Scholar
• Roytman M, Frumkin A, Bohn TG. Pseudotumor cerebri caused by isotretinoin. Cutis 1988;42(5):399-400
   PubMedGoogle Scholar
• Fraunfelder FW, Fraunfelder FT, Corbett JJ. Isotretinoin-induced intracranial hypertension. Ophthalmology 2004;111(6):1248-50
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW, Fraunfelder FT. Evidence for a probable causal relationship between tretinoin, acitretin, and etretinate and intracranial hypertension. J Neuroophthalmol 2004;24(3):214-6
   PubMed Web of Science ®Google Scholar
• Orfanos CE. Retinoids: the new status. Maintenance therapy, disorders of resorption in “non-responders”, interactions and interferences with drugs, treatment of children and bone toxicity, acitetin and 13-cis-acitretin. Hautarzt 1989;40(3):123-9
   PubMed Web of Science ®Google Scholar
• Prendiville J, Bingham EA, Burrows D. Premature epiphyseal closure – a complication of etretinate therapy in children. J Am Acad Dermatol 1986;15(6):1259-62
   PubMed Web of Science ®Google Scholar
• Gilbert M, Ellis CN, Voorhees JJ. Lack of skeletal radiographic changes during short-term etretinate therapy for psoriasis. Dermatologica 1986;172:160-3
   PubMedGoogle Scholar
• Guit GL, Obermann WR, van der Schroeff JG, Sillevis-Smitt HJ. Cortical hyperostosis and enthesopathy due to long-term etretinate administration. Diagn Imaging Clin Med 1986;55:214-8
   PubMedGoogle Scholar
• DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001;45:S176-182
   PubMed Web of Science ®Google Scholar
• Lee E, Koo J. Single-center retrospective study of long-term use of low-dose acitretin (Soriatane®) for psoriasis. J Dermatol Treat 2004;15:8-13
   PubMedGoogle Scholar
• Davidson MH, Stein EA, Bays HE, et al. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators: efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29(7):1354-67
   PubMed Web of Science ®Google Scholar
• Koo J, Nguyen Q, Leach EE. Advances in psoriasis therapy. Adv Dermatol 1997;12:47-72
   PubMedGoogle Scholar
• Roenigk HH Jr, Callen JP, Guzzo CA, et al. Effects of acitretin on the liver. J Am Acad Dermatol 1999;41:584-8
   PubMed Web of Science ®Google Scholar
• Stern RS, Fitzgerald E, Ellis CN, et al. The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 1995;33:44-52
   PubMed Web of Science ®Google Scholar